Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Thoracic Malignancies
What target volumes and expansions would you use for neoadjuvant chemoradiotherapy to a large thymoma with the goal of shrinking the tumor to aid resectability?
Would you include a CTV, and if so, how would you account for proximity to the heart?
Related Questions
How would you manage adjuvant therapy for a patient with pulmonary adenoid cystic carcinoma s/p resection with positive bronchial and vascular margins and nodal involvement?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
Should we repeat a dose-escalation trial for stage III NSCLC in the era of modern radiotherapy techniques and dose constraints?
Would you offer any degree of hypofractionation with concurrent chemotherapy for NSCLC?
Would you offer postoperative radiation for a patient who initially had biopsy-proven multistation N2 NSCLC but had a nodal pCR upon surgical resection+ LND after neoadjuvant chemo-immunotherapy?
What ipsilateral lung constraints if any do you utilize for SBRT and or hypofractionated RT in the lungs?
What are best practices for oncologists during the national platinum shortage?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
How do the results of TROPION-Lung01 Phase III trial change your practice in the management of locally advanced or metastatic NSCLC?
Would you give RT to a young BAP1+ patient with lung cancer s/p NAC and P/D who has biopsy-proven pleural recurrence after adjuvant chemo?